Navigation Links
Lilly Declares Fourth-Quarter 2010 Dividend
Date:10/18/2010

INDIANAPOLIS, Oct. 18 /PRNewswire-FirstCall/ -- The board of directors of Eli Lilly and Company (NYSE: LLY) today declared a dividend for the fourth quarter of 2010 of $0.49 a share on outstanding common stock. This is the same dividend as was paid in the first three quarters of 2010 and brings the total annual dividend for 2010 to $1.96 per share.

The dividend is payable December 10, 2010 to shareholders of record at the close of business on November 15, 2010.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers – through medicines and information – for some of the world's most urgent medical needs.  Additional information about Lilly is available at www.lilly.com.  F-LLY

(Logo: http://www.newscom.com/cgi-bin/prnh/20031219/LLYLOGO)

(Logo: http://photos.prnewswire.com/prnh/20031219/LLYLOGO)


'/>"/>
SOURCE Eli Lilly and Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Lilly Confirms Date and Conference Call for Third-Quarter 2010 Financial Results Announcement
2. Lilly CEO Says Regional Innovation Clusters Can Renew the Nations Economy
3. Reportlinker Adds Eli Lilly & Co.: PharmaVitae Profile
4. Lilly Celebrates 16th Consecutive Year as One of 100 Best Companies for Working Mothers
5. Lilly Recognized with World Business and Development Award for Tuberculosis Initiative
6. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
7. U.S. Court of Appeals Reverses Third-Party Payor Class Certification Suit Against Lilly
8. U.S. Court of Appeals Upholds Validity of Lillys Evista Patents Through March of 2014
9. Statement from Eli Lilly and Company Regarding Approval Recommendation from FDA Advisory Committee for Expanding the Pain Indications for Cymbalta® to a Broader Pain Population
10. Lilly Halts Development of Semagacestat for Alzheimers Disease Based on Preliminary Results of Phase III Clinical Trials
11. The American Diabetes Association and Eli Lilly and Company Encourage African-Americans to Face the Music about Diabetes Management
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Research and Markets has announced the addition ... 2022" report to their offering. ... with kidney failure, it replaces the function of kidneys by ... and thus the treatment helps to keep the patient body,s ... Increasing number of ESRD patients & substantial healthcare ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... June 23, 2016 Capricor ... ), a biotechnology company focused on the discovery, ... that patient enrollment in its ongoing randomized HOPE-Duchenne ... exceeded 50% of its 24-patient target. Capricor expects ... third quarter of 2016, and to report top ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Austin residents seeking Mohs surgery ... of Mohs Surgery and to Dr. Russell Peckham for medical and surgical dermatology. , ... for skin cancer. The selective fellowship in Mohs Micrographic Surgery completed by Dr. Dorsey ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures as ... City area —Johnson is one of the first doctors to perform the treatment. ...
(Date:6/24/2016)... , ... June 24, 2016 , ... June 19, 2016 ... dangers associated with chronic pain and the benefits of holistic treatments, Serenity Recovery ... are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a disorder ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA ... the Road To Recovery® program to drive cancer patients to and from their cancer ... ensure the highest quality of life and ongoing independence. Getting to and from ...
(Date:6/24/2016)... ... June 24, 2016 , ... Puradigm® ... Group (TGIG), has initiated cultivation and processing operations at its production facility, and ... Nevada. , Puradigm is the manufacturer of a complete system of proactive air ...
Breaking Medicine News(10 mins):